Gossamer Bio
Yahoo Finance • 16 hours ago
GOSSAMER DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the “Class... Full story
Yahoo Finance • 16 hours ago
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS
SAN FRANCISCO, May 27, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer secu... Full story
Yahoo Finance • yesterday
DEADLINE ALERT for GOSS, NUAI, and MEDP: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
LOS ANGELES, May 27, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the de... Full story
Yahoo Finance • 2 days ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyto... Full story
Yahoo Finance • 2 days ago
DEADLINE APPROACHING: Berger Montague Advises Gossamer Bio, Inc. (NASDAQ: GOSS) Investors to Inquire About a Securities Fraud Class Action by June 1, 2026
PHILADELPHIA, May 26, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) (“Gossamer” or the “Company”) on behalf of investors who purchased... Full story
Yahoo Finance • 3 days ago
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, May 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) for vio... Full story
Yahoo Finance • 6 days ago
GOSS 10-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
SAN FRANCISCO, May 22, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer secu... Full story
Yahoo Finance • 6 days ago
הודעת מועד אחרון לתביעה ייצוגית נגד GOSSAMER: רוזן, יועץ למשקיעים מוביל, מעודד משקיעים ב- Gossamer Bio, Inc. עם הפסדים של יותר מ-100 אלף דולר לקבל ייעוץ משפטי לפני המועד האחרון החשוב בתביעה ייצוגית לניירות ערך – GOSS
ניו יורק, May 22, 2026 (GLOBE NEWSWIRE) -- מדוע: משרד רוזן עורכי דין (Rosen Law Firm), משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, מזכיר לרוכשים את ניירות הערך של Gossamer Bio, Inc. (נאסד"ק: GOSS) בין התאריכים 16ביוני2025 עד 20בפברו... Full story
Yahoo Finance • 7 days ago
GOSSAMER DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the “Class... Full story
Yahoo Finance • 7 days ago
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and certain o... Full story
Yahoo Finance • 9 days ago
DEADLINE ALERT for PINS, NUAI, GOSS, MEDP: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
BENSALEM, Pa. , May 19, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story
Yahoo Finance • 9 days ago
Gossamer Bio Q1 Net Loss Expands; Eyes On The Pre-NDA Meeting With FDA For Seralutinib W In Mid-June
(RTTNews) - Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company, on Monday announced its financial results for the first quarter ended March 31, 2026, reflecting a wider net loss and provided a near-term milestone update... Full story
Yahoo Finance • 10 days ago
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the “Class... Full story
Yahoo Finance • 10 days ago
Gossamer targets September 2026 seralutinib NDA filing with potential Q3 2027 approval
Earnings Call Insights: Gossamer Bio (GOSS) Q1 2026 MANAGEMENT VIEW * CEO Faheem Hasnain framed PROSERA’s topline as clinically meaningful but statistically mixed: "PROSERA showed a clinically meaningful placebo-adjusted improvement of... Full story
Yahoo Finance • 10 days ago
Gossamer Bio Q1 Earnings Call Highlights
Key Points Interested in Gossamer Bio, Inc.? Here are five stocks we like better. Gossamer Bio is still targeting a September 2026 NDA submission for seralutinib in pulmonary arterial hypertension, with a June FDA pre-NDA meeting set to h... Full story
Yahoo Finance • 11 days ago
Here are the major earnings before the open Monday
Major earnings expected before the bell on Monday include: * Baidu (BIDU [https://seekingalpha.com/symbol/BIDU]) * iQIYI (IQ [https://seekingalpha.com/symbol/IQ]) * Ryanair Holdings plc (RYAAY [https://seekingalpha.com/symbol/RYAAY]... Full story
Yahoo Finance • 18 days ago
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
NEW YORK, May 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the “Class... Full story
Yahoo Finance • 20 days ago
INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action– Hagens Berman
SAN FRANCISCO, May 08, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer secu... Full story
Yahoo Finance • 24 days ago
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Provided Inadequate Disclosures: Levi & Korsinsky
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP examines the adequacy of Gossamer Bio, Inc.'s (NASDAQ: GOSS) risk disclosures in connection with a pending securities class action. Evaluate whether you qualify to recover... Full story
Yahoo Finance • 24 days ago
ROSEN, A LONGSTANDING LAW FIRM, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the “Class... Full story